Treating cancer with PEG Intron: pharmacokinetic profile and dosing guidelines for an improved interferon-alpha-2b formulation. - Wikidata - awgldk - TriplyDB

Treating cancer with PEG Intron: pharmacokinetic profile and dosing guidelines for an improved interferon-alpha-2b formulation.

Treating cancer with PEG Intron: pharmacokinetic profile and dosing guidelines for an improved interferon-alpha-2b formulation.

http://www.wikidata.org/entity/Q34747443

about

Advances in PEGylation of important biotech molecules: delivery aspects Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good R Combination immunotherapy for high-risk resected and metastatic melanoma patients Next generation delivery system for proteins and genes of therapeutic purpose: why and how?Pharmacokinetic/pharmacodynamic analysis of adjuvant pegylated interferon α-2b in patients with resected high-risk melanoma.Evolving role of pegylated interferons in metastatic renal cell carcinoma.Cutaneous T-cell lymphoma: a paradigm for biological therapies.Single-dose pharmacokinetics and tolerability of pegylated interferon-alpha2b in young and elderly healthy subjects.Exploiting antitumor immunity to overcome relapse and improve remission duration.Inhibition effect of Peg-IFNα-2b and Imatinib alone or combination on imatinib-resistant gastrointestinal stromal tumors cell lines.U.S. Food and Drug Administration Approval: peginterferon-alfa-2b for the adjuvant treatment of patients with melanoma.Strategies and developments of immunotherapies in osteosarcoma Pharmacokinetic consequences of pegylation.Depletion of T lymphocytes is correlated with response to temozolomide in melanoma patients.Feasibility of Pegylated Interferon in Children and Young Adults With Resected High-Risk Melanoma.Novel delivery systems for interferons.PEGylated interferon beta-1a in the treatment of multiple sclerosis - an update.Immunotherapy of distant metastatic disease.Tumor angiogenesis: insights and innovations.Drug delivery strategies for therapeutic angiogenesis and antiangiogenesis.A new era for IFN-α in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms.An update on pegylated IFN-α2b for the adjuvant treatment of melanoma.Designing PEGylated therapeutic molecules: advantages in ADMET properties.Therapeutic oligonucleotides with polyethylene glycol modifications.Evidence of bias in randomized clinical trials of hepatitis C interferon therapies.Pegylated interferon alpha 2b for treatment of ocular surface squamous neoplasia: a pilot study.Poly(ethylene glycol)-Prodrug Conjugates: Concept, Design, and Applications Adjuvant pegylated interferon α-2b therapy for melanoma Pegylated-interferon induced severe bone marrow hypoplasia in a patient with multiple myeloma receiving thalidomide.Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis.Pegylated interferon-alpha protects type 1 pneumocytes against SARS coronavirus infection in macaques.Phase II study of temozolomide plus pegylated interferon-alpha-2b for metastatic melanoma.Comparison of pegylated interferon α-2b plus psoralen PUVA versus standard interferon α-2a plus PUVA in patients with cutaneous T-cell lymphoma.Pegylated recombinant interferon alpha-2b vs recombinant interferon alpha-2b for the initial treatment of chronic-phase chronic myelogenous leukemia: a phase III study.Treatment with IFNalpha in vivo up-regulates serum-soluble TNF-related apoptosis inducing ligand (sTRAIL) levels and TRAIL mRNA expressions in neutrophils in chronic myelogenous leukemia patients.A cross-sectional study of the availability and pharmacist's knowledge of nano-pharmaceutical drugs in Palestinian hospitals.

P2860

Q28277255-9A4A25B8-A0AF-4C49-A35E-1E9958437859 Q30357731-F1678D89-100F-469C-8D16-DF509FE987B8 Q33737498-1E9C05B9-F473-46A7-9459-E6B3310BC9F7 Q34003800-84D26E46-8878-4D6C-8FE2-E73224120C0A Q34594791-D0ACD474-F2B7-4B09-A625-71B373E79FC1 Q35611876-ACBF5791-7E28-4E53-B472-786E8C532596 Q35821012-9BD3E65D-F8EB-423C-9CB7-45095ED3EF17 Q35825645-635955AB-5C2A-4C4E-A5B8-1796CD929961 Q36044604-5FE46058-BB3E-455F-94C0-FC976C7F2783 Q36261782-54F3F613-227D-4CEA-B4EA-100BB0BC0FA9 Q36349616-67D7D0DB-6806-4DBD-96D5-000BB4E8D5AD Q36503128-4D427733-B5F4-4F0C-89A5-E82808AFC49A Q36604526-E0A54A50-E4CC-462F-9032-8575F074BC4B Q36694942-BBBBD40C-A3F5-4026-A4B4-2BA6E8D6CF57 Q36927476-52A91A4C-FC47-44AA-BC89-1D420CC6A74A Q36937971-007D7DCB-95C0-478A-A395-040203507232 Q36940229-B301597B-F6D5-453C-B39D-4F117A46AA59 Q37266668-617CF310-4B8F-4FFA-8345-043F8E8A8F36 Q37743207-99035580-8FD1-4386-BBEA-EFE97B056861 Q37845396-B5F79F89-456B-4B9B-9B75-DC8ED06DA06A Q37955231-7DD7F764-F71F-4DE8-A966-AB582258D63E Q38068207-25AB4C92-83A5-4FC8-95AA-49F59A873617 Q38089879-92D9D544-C8F4-47CB-B8E8-779B7F1C49A3 Q38296021-0FECF86F-C900-489E-9C33-8C5C674FFA93 Q38697250-F154106F-ECB7-451E-9CCF-9C0B17FDEA01 Q39853218-B3999B43-846F-46B2-8775-73AFBB1DA773 Q42175440-9C98DAEC-00E3-41A6-BD26-19DEC1526777 Q42323673-A41F38E4-6EA0-4780-BBDD-E23D78C518FE Q44667235-9D3402F7-2E05-4703-A967-5C107A2D7E41 Q46636672-9BDC4CE6-6EB5-492F-9216-BF361C13D3DA Q48015946-3560DE38-542C-4B87-81D7-2F787FFA5ECC Q48567066-38172356-EE39-4203-89E3-089BB1E14D27 Q52767066-06441F4D-78F0-4CEE-A54B-60CEB842D318 Q53294924-786D5FF0-0B8B-49C0-9EC2-922AEDDBEB7D Q53559624-5485C288-C565-41D5-9377-52B673B1512E Q55045079-7B86F356-7527-483D-9885-034B0F54AFF7

P2860

Treating cancer with PEG Intron: pharmacokinetic profile and dosing guidelines for an improved interferon-alpha-2b formulation.

http://www.wikidata.org/entity/Q34747443

description

2002 nî lūn-bûn

@nan

2002 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

Treating cancer with PEG Intro ...... terferon-alpha-2b formulation.

@ast

Treating cancer with PEG Intro ...... terferon-alpha-2b formulation.

@en

Treating cancer with PEG Intro ...... terferon-alpha-2b formulation.

@nl

type

label

Treating cancer with PEG Intro ...... terferon-alpha-2b formulation.

@ast

Treating cancer with PEG Intro ...... terferon-alpha-2b formulation.

@en

Treating cancer with PEG Intro ...... terferon-alpha-2b formulation.

@nl

prefLabel

Treating cancer with PEG Intro ...... terferon-alpha-2b formulation.

@ast

Treating cancer with PEG Intro ...... terferon-alpha-2b formulation.

@en

Treating cancer with PEG Intro ...... terferon-alpha-2b formulation.

@nl

P1433

Q34747443-0342B01F-C134-43E7-9470-48DBC56CBC1B

P1476

Q34747443-1DD5D164-7C73-4C1C-B82F-9098BE106427

P2093

Q34747443-2E920488-6913-415C-B488-CE726C9FB1A7

Q34747443-2FF04398-88DC-4605-A9DB-6B4E2AB687A7

Q34747443-3D0DDE1E-AE68-469E-A297-B2026A059275

Q34747443-4C433361-4314-45D6-A26C-8B8300A570C5

Q34747443-DB1B9DA4-130E-4EA9-BEBB-AAD34C111721

Q34747443-FC41AEC2-E5CB-4E4C-AC30-D2026E7CBBAA

P2860

Q34747443-3CE3602A-FE13-4518-9962-7AF2DE5B9173

Q34747443-548B90E1-ABFC-4060-8527-8C59EC2CA13B

Q34747443-5F153454-D2E4-4655-80C4-F89DAFD09CC1

Q34747443-880AD4B9-4C77-4CEA-BC2D-859F05A8DB0F

Q34747443-A079501E-3B9F-45BF-9969-4243492D1661

Q34747443-A320EB7B-2B27-4B76-A1BD-84BA4075F6A0

Q34747443-D994CE59-9322-409C-89DD-433C073E397D

Q34747443-F116D862-43DC-4999-8A2E-50AAAC97AC1D

P304

Q34747443-5E26116D-B3E4-42E6-8B49-49B5292C4B58

P31

Q34747443-237CBF22-62DD-4A81-AFD4-C7D6CEA20A7E

P356

Q34747443-4D0F6BD1-D1BB-4720-84EE-7D248B84AB64

P407

Q34747443-96322B51-9792-444A-A4F5-BEB32264527E

P433

Q34747443-2F626264-6284-481E-9004-6876E797BDD5

P478

Q34747443-ABFD657F-D836-4B6E-93AB-69C43B932C2B

P577

Q34747443-8480A8D6-954E-4309-952D-423AA54E545F

P5875

Q34747443-B5CD94E3-19BF-4AD6-9325-BB7FA15B3148

P698

Q34747443-D30B719E-7202-401B-A264-3CF98A37C433

P356

P1433

P1476

Treating cancer with PEG Intro ...... terferon-alpha-2b formulation.

@en

P2093

Craig Tendler

http://www.w3.org/2001/XMLSchema#string

David Cutler

http://www.w3.org/2001/XMLSchema#string

Esther Rose

http://www.w3.org/2001/XMLSchema#string

Mark M Laughlin

http://www.w3.org/2001/XMLSchema#string

Paul Statkevich

http://www.w3.org/2001/XMLSchema#string

Ronald M Bukowski

http://www.w3.org/2001/XMLSchema#string

P2860

Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group.

Objective antiviral assay of the interferons by computer assisted data collection and analysis.

Biomedical and biotechnological applications of PEG- and PM-modified proteins.

Pegaspargase: an alternative?

A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C.

PEG-ADA replacement therapy for adenosine deaminase deficiency: an update after 8.5 years.

Long-acting growth hormones produced by conjugation with polyethylene glycol.

Phase 1 study of polyethylene glycol formulation of interferon alpha-2B (Schering 54031) in Philadelphia chromosome-positive chronic myelogenous leukemia.

P304

389-396

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CNCR.10663

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

95

http://www.w3.org/2001/XMLSchema#string

P577

2002-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11254210

http://www.w3.org/2001/XMLSchema#string

P698

12124839

http://www.w3.org/2001/XMLSchema#string